News reports this week have detailed the research of Canadian scientists Dr Paolo Zamboni, who is a professor of medicine at the University of Ferrara in Italy and whose wife has multiple sclerosis (MS). Dr Zamboni claims from his studies of MS literature to have discovered what he believes could be a revolution for the treatment and diagnosis of the life-long condition.

See more here:
Husband’s Studies Lead To Clinical Trial – Multiple Sclerosis Society

Related posts:

1. Childbirth May Slow MS – Multiple Sclerosis SocietyResearchers in Belgium have suggested that giving birth slows the progression of multiple sclerosis (MS). The results of their study are published in the Journal of Neurology Neurosurgery and Psychiatry....
2. Mayo Clinic Neurologist Reports: "Thousands Of NMO Patients Are Misdiagnosed With Multiple Sclerosis"Thousands of Neuromyelitis Optica (NMO) patients are potentially being misdiagnosed with Multiple Sclerosis (MS), according to Mayo Clinic Neurologist Sean Pittock, M.D., largely due to lack of awareness of NMO...
3. Multiple Sclerosis: What Part Do Relapses Play In Severe Disability?People with multiple sclerosis (MS) who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do...
4. Real-Time Observation Sheds New Light On Multiple SclerosisIn diseases such as multiple sclerosis, cells of the immune system infiltrate the brain tissue, where they cause immense damage. For many years, it was an enigma as to how...
5. Study Confirms That Cannabis Is Beneficial For Multiple SclerosisCannabis can reduce spasticity in multiple sclerosis (MS) patients. A systematic review, published in the open access journal BMC Neurology, found that five out six randomized controlled trials reported a...
6. Human Genome Sciences And Aegera Therapeutics Announce Initiation Of Clinical Trial Of Lead IAP Inhibitor HGS1029 In Advanced Lymphoid TumorsHuman Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its...
7. Gloucester Pharmaceuticals To Present Positive Results From Multiple Studies Of ISTODAX(R) At The ASH Annual MeetingGloucester Pharmaceuticals announced multiple presentations from clinical and preclinical studies of ISTODAX® (romidepsin) at the upcoming 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, Louisiana,...
8. Three Important Points – Multiple Sclerosis TreatmentWhen it comes to neurological diseases which are debilitating, Multiple Sclerosis is the one most commonly found amongst the young. It is usually strikes between the ages of 20 and...
9. Repligen Reports Phase 3 Clinical Trial Results Of RG1068 In Pancreatic ImagingRepligen Corporation (Nasdaq: RGEN) reported top-line results from a Phase 3 clinical trial to evaluate the safety and efficacy of RG1068, synthetic human secretin, to improve magnetic resonance imaging (MRI)...
10. PanGenex Expands Clinical Trial Sites After Promising Pre-Clinical Data About Lower Coronary Arterial Calcium Scores In Cardiac PatientsPanGenex Corporation (Pink Sheets: PGCX) ("PanGenex" or "the Company") announced that due to promising pre-clinical results from its clinical trial at the Cardiovascular Institute of the South (http://www.cardio.com/site1.php), the Company...
11. Curemark Opens Patient Enrollment For Autism Treatment At Three More Clinical Trial SitesCuremark LLC, a drug research and development company focused on the treatment of neurological diseases, announced that the company has begun enrolling patients in Phase III clinical trials for CM-AT,...
12. Resverlogix Commences Phase 2 Atherosclerosis Clinical TrialResverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208,...
13. Memgen’s Clinical Trial Results Of ISF35 For Chronic Lymphocytic Leukemia Selected For Presentation At ASH 2009 Annual MeetingMemgen announced today that results from its ongoing, Leukemia & Lymphoma Society co-sponsored clinical trial in chronic lymphocytic leukemia (CLL) have been selected for an oral presentation at the 51st...
14. ERYtech Pharma Starts Its Pivotal Clinical Trial For GRASPA(R) In Acute Lymphoblastic LeukaemiaERYtech Pharma announces the start of its pivotal clinical trial for GRASPA®, its lead product in Acute Lymphoblastic Leukaemia. This phase III trial has begun in France and will be...
15. Boehringer Ingelheim Initiates First Phase III Clinical Trial In Ovarian CancerBoehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced...